RecruitingNot ApplicableNCT07323043

Effect of Tegileridine Versus Sufentanil as Analgesic Components on Opioid-Induced Cough During Anesthesia Induction

The Affiliated Lianyungang Hospital of Xuzhou Medical University

Sponsor

The First People's Hospital of Lianyungang

Enrollment

190 participants

Start Date

Jan 15, 2026

Study Type

INTERVENTIONAL

Conditions

General Anesthetic Drug Adverse Reaction

Summary

In patients undergoing general anesthesia with planned tracheal intubation , a prospective, randomized, controlled study was conducted to record the occurrence of cough 2 minutes after injection of Sufentanil or Tegilerdine. The cough was graded based on the frequency and duration: Grade I, no cough; Grade II, a single mild cough; Grade III, multiple coughs with duration \<1 second; Grade IV, continuous coughing with a duration \>15 seconds.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Sufentanil and a drug called Tegilerdine for people with general anesthetic drug adverse reaction. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.